Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference
Version of Record online: 30 JUL 2008
© 2008 The Authors. Journal Compilation © 2008 Blackwell Publishing Ltd
British Journal of Haematology
Volume 142, Issue 6, pages 859–876, September 2008
How to Cite
Vlachos, A., Ball, S., Dahl, N., Alter, B. P., Sheth, S., Ramenghi, U., Meerpohl, J., Karlsson, S., Liu, J. M., Leblanc, T., Paley, C., Kang, E. M., Leder, E. J., Atsidaftos, E., Shimamura, A., Bessler, M., Glader, B., Lipton, J. M. and on behalf of the participants of the Sixth Annual Daniella Maria Arturi International Consensus Conference (2008), Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. British Journal of Haematology, 142: 859–876. doi: 10.1111/j.1365-2141.2008.07269.x
- Issue online: 21 AUG 2008
- Version of Record online: 30 JUL 2008
- Diamond Blackfan anaemia;
- bone marrow failure;
- cancer predisposition;
Diamond Blackfan anaemia (DBA) is a rare, genetically and clinically heterogeneous, inherited red cell aplasia. Classical DBA affects about seven per million live births and presents during the first year of life. However, as mutated genes have been discovered in DBA, non-classical cases with less distinct phenotypes are being described in adults as well as children. In caring for these patients it is often difficult to have a clear understanding of the treatment options and their outcomes because of the lack of complete information on the natural history of the disease. The purpose of this document is to review the criteria for diagnosis, evaluate the available treatment options, including corticosteroid and transfusion therapies and stem cell transplantation, and propose a plan for optimizing patient care. Congenital anomalies, mode of inheritance, cancer predisposition, and pregnancy in DBA are also reviewed. Evidence-based conclusions will be made when possible; however, as in many rare diseases, the data are often anecdotal and the recommendations are based upon the best judgment of experienced clinicians. The recommendations regarding the diagnosis and management described in this report are the result of deliberations and discussions at an international consensus conference.